Clinical trials: Wasting
Muscle Wasting, Non Small Cell Lung Cancer
Phase III Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
- Trial name
- NCT01355484
- Testing
- GTx-024
- Where
- 27 sites in United States
- Volunteers
- 321 people
- Sponsor
- GTx
HCC
Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)
The purpose of this study is to determine if VT-122 provides a clinical benefit when added to Sorafenib in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT01265576
- Testing
- Sorafenib, VT-122 (propranolol plus etodolac)
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Vicus Therapeutics
Cachexia-Anorexia Syndrome, Cachexia; Cancer
A Phase II Clinical Study Evaluating the Efficacy and Safety of SXRN Injection in Patients With Cancer Cachexia
This is a multicenter, randomized, double-blind, placebo-controlled, dose-finding Phase II clinical study to evaluate the efficacy and safety of SXRN injection in adult patients with cancer-associated anorexia-cachexia.
- Trial name
- NCT07890324
- Testing
- SXRN Injection
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Jiangsu Guiqiong Pharmaceutical Co., Ltd.
Anorexia, Cachexia
Treatment of Cancer-anorexia Using Megestrol Acetate Concentrated Suspension in Lung or Pancreatic Cancer Patients
Purpose of the study is to compare the effects of megestrol acetate concentrated suspension and placebo on caloric intake for the treatment of cancer-associated anorexia in patients with lung or pancreatic cancer
- Conditions
- Anorexia, Cachexia, Weight Loss
- Trial name
- NCT00637728
- Testing
- Megestrol acetate concentrated suspension 110 mg/mL
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Par Pharmaceutical, Inc.
Hypercatabolic Status Related to Severe Burn
Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects
Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks
- Trial name
- NCT02074995
- Testing
- BVS857
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
NON-SMALL CELL LUNG CANCER
Effect of IMN1207 Versus Casein on Weight Loss, Survival and Quality of Life in Non-small Cell Lung Cancer Patients
The primary aim of this IMN 1207 follow-up study is to confirm the effect of a cysteine-rich non-denatured whey protein isolate formulation IMN1207 (20g daily) versus casein (20 g daily) on the reversal of weight loss…
- Trial name
- NCT01046383
- Testing
- IMN1207, Casein
- Where
- 5 sites in Canada
- Volunteers
- 16 people
- Sponsor
- Immunotec Inc.
Cancer, Cachexia
Study of the Safety and Efficacy of DS010 in Patients With Cancer Cachexia
A study to evaluate the safety, tolerability, and preliminary efficacy of DS010 in patients with cancer and cachexia
- Trial name
- NCT07530666
- Testing
- DS010 injection
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Dartsbio Pharmaceuticals Ltd.
Sporadic Inclusion Body Myositis
Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
This study evaluated the efficacy, safety and tolerability of multiple doses of bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function, muscle strength, and mobility in patients with sporadic…
- Trial name
- RESILIENT (NCT01925209)
- Testing
- BYM338/bimagrumab
- Where
- 38 sites in United States, Australia and 8 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Cancer Cachexia
Placebo Controlled, Randomized Safety and Efficacy Study of RC-1291 in Cancer Anorexia/Cachexia.
Anorexia and cachexia are devastating complications in late-stage cancer patients and is strongly associated with mortality in these patients. Activation of Ghrelin receptors have been demonstrated to stimulate appetite.
- Trial name
- NCT00267358
- Testing
- RC-1291 HCl
- Where
- 19 sites in United States
- Sponsor
- Helsinn Therapeutics (U.S.), Inc
Anorexia, Cachexia
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS.
- Conditions
- Anorexia, Cachexia, HIV Infections
- Trial name
- NCT00002067
- Testing
- Megestrol acetate
- Where
- 14 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections, Cachexia
Evaluate Weight Gain Using 2 Different Formulations of Megestrol Acetate Oral Suspension for AIDS-related Weight Loss
Explore weight gain in HIV-positive patients who have weight loss associated with AIDS-related wasting (anorexia/cachexia). Patients are treated for 12 weeks with either megestrol acetate oral suspension nanocrystal dispersion…
- Conditions
- HIV Infections, Cachexia, Anorexia, AIDS Wasting Syndrome
- Trial name
- NCT00637572
- Testing
- Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL, Megestrol acetate oral suspension 40 mg/mL
- Where
- 12 sites in United States, India and 1 more
- Volunteers
- 63 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Cancer Weight Loss
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
This is a randomized, double-blind, placebo-controlled basket trial evaluating mifomelatide (TCMCB07) administered daily by subcutaneous (SC) injection in up to 120 patients.
- Trial name
- NCT06937177
- Testing
- TCMCB07
- Where
- 26 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Endevica Bio
Anorexia, Cachexia
Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer
The purpose of this study is to determine whether Betamarc is effective in improving the appetite and reversing weight loss in patients with advanced Non-Small Cell Lung Cancer.
- Conditions
- Anorexia, Cachexia, Weight Loss, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT00535015
- Testing
- Betamarc
- Where
- 6 sites in China, Taiwan
- Volunteers
- 70 people
- Sponsor
- Anaborex
Advanced Cancer, Cachexia
A Phase I Study on Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of SXRN Plasmid DNA Technique in Patients With Advanced Solid Tumors
The purpose of this clinical trial is to evaluate the safety and tolerability of SXRN Plasmid DNA Technique in patients with advanced solid tumors.
- Trial name
- NCT06736275
- Testing
- SXRN
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Jiangsu Nutai Biologics Co., Ltd
Cannabis Use, Cachexia; Cancer
Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
A large number of patients with advanced cancer also suffer from cachexia. Cachexia is a syndrome characterized by loss of skeletal muscle mass (with/or without loss of fat mass) that cannot be reversed by nutritional support and…
- Conditions
- Cannabis Use, Cachexia; Cancer, Advanced Cancer
- Trial name
- SERENITY (NCT04001010)
- Testing
- PPP011
- Where
- Canada
- Volunteers
- 334 people
- Sponsor
- Tetra Bio-Pharma
Chronic Obstructive Pulmonary Disease (COPD) With Cachexia
BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh muscle volume compared to placebo.
- Trial name
- NCT01669174
- Testing
- BYM338
- Where
- 9 sites in United States, Netherlands and 1 more
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Anorexia, Cancer Cachexia
Open Label Study With OHR/AVR118 in Advanced Cancer Patients With Anorexia-Cachexia
The purpose of this study is to determine whether patients with advanced cancers who receive OHR/AVR118 solution for injection into the skin can achieve improvement in quality of life.
- Trial name
- NCT01206335
- Testing
- OHR/AVR118
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Ohr Pharmaceutical Inc.
Cachexia, Digestive System Cancer
Real-World Study on Nano-Crystalline Megestrol Acetate for Cachexia in TKI-Treated Advanced Digestive Tumors
This study is a prospective, observational clinical study aimed at evaluating the efficacy of Megestrol Acetate for cachexia in patients with advanced digestive system tumors receiving TKI-based therapy.
- Conditions
- Cachexia, Digestive System Cancer, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT06940102
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, TKI-Based Therapy
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Cachexia, Non-Small-Cell Lung Cancer
Study to Assess the Safety and Tolerability of Repeated Doses of an Investigational New Drug in Patients With Cancer and Cachexia.
Study to assess the safety and tolerability of repeated doses of an investigational new drug in patients with cancer and cachexia.
- Conditions
- Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT04299048
- Testing
- PF-06946860
- Where
- 10 sites in United States
- Volunteers
- 11 people
- Sponsor
- Pfizer
Cachexia
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2849466 in Healthy Male Subjects
This study is the first administration of GSK2849466 in humans. This will be a single centre, randomized, double-blind, placebo-controlled study, to investigate the safety, tolerability, pharmacokinetics (PK), and…
- Trial name
- NCT01696604
- Testing
- GSK2849466
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline